A mammalian N-acetylglucosamine (GlcNAc) transferase I (GnT I)-independent fucosylation pathway is revealed by the use of matrix-assisted laser desorption/ionization (MALDI) and negative-ion nano-electrospray ionization (ESI) mass spectrometry of N-linked glycans from natively folded recombinant glycoproteins, expressed in both human embryonic kidney (HEK) 293S and Chinese hamster ovary (CHO) Lec3.2.8.1 cells deficient in GnT I activity. The biosynthesis of core fucosylated Man 5 GlcNAc 2 glycans was enhanced in CHO Lec3.2.8.1 cells by the a-glucosidase inhibitor, N-butyldeoxynojirimycin (NB-DNJ), leading to the increase in core fucosylated Man 5 GlcNAc 2 glycans and the biosynthesis of a novel core fucosylated monoglucosylated oligomannose glycan, Glc 1 Man 7 GlcNAc 2 Fuc. Furthermore, no fucosylated Man 9 GlcNAc 2 glycans were detected following inhibition of a-mannosidase I with kifunensine. Thus, core fucosylation is prevented by the presence of terminal a1-2 mannoses on the 6-antennae but not the 3-antennae of the trimannosyl core. Fucosylated Man 5 GlcNAc 2 glycans were also detected on recombinant glycoprotein from HEK 293T cells following inhibition of Golgi a-mannosidase II with swainsonine. The paucity of fucosylated oligomannose glycans in wild-type mammalian cells is suggested to be due to kinetic properties of the pathway rather than the absence of the appropriate catalytic activity. The presence of the GnT I-independent fucosylation pathway is an important consideration when engineering mammalian glycosylation.
Introduction
The N-linked glycosylation pathways of higher eukaryotes contain a multitude of biosynthetic reactions that give rise to a wide diversity of glycan structures. Despite this complexity, there are two ancient and highly conserved enzymatic steps that mediate the sequential conversion of oligomannose glycans to hybrid-type and then to complextype structures. The conversion of oligomannose-type to hybrid-type glycans is initiated by the action of UDP-Nacetyl-D-glucosamine:α-3-D-mannoside β1,2-N-acetylglucosaminyltransferase I (GnT I) which transfers N-acetylglucosamine (GlcNAc), in a β1-2 linkage, to the 3-arm mannose residue of the oligomannose substrate, Man 5 GlcNAc 2 (Choi et al., 2003) . The transfer of this GlcNAc is the essential step for the generation of complextype glycans that form after the subsequent cleavage of the two 6-arm mannose residues by Golgi α3,6-mannosidase II. Thus, formation of all complex glycans proceeds via the hybrid intermediate, GlcNAcβ1-2Man 5 GlcNAc 2 . GnT I activity is often considered absolutely required for the action of other glycosyltransferases, including the mammalian core α1,6-fucosyltransferase which catalyses the addition of α1-6-linked fucose (Fuc) to the reducing end GlcNAc (Wilson et al., 1976; Longmore and Schachter, 1982; Voynow et al., 1991) , as well as the plant and insect core α1,3-fucosyltransferases (Johnson and Chrispeels, 1987; von Schaewen et al., 1993; Staudacher et al., 1995; Leiter et al., 1999; Strasser et al., 2005) .
There are, however, a number of reports of an alternative pathway in which the core fucosylation occurs independently of GnT I activity. For example, fucosylated paucimannose and oligomannose glycans have been identified in the nematode worm C. elegans (Haslam and Dell, 2003; Zhang et al., 2003; Zhu et al., 2004) . In C. elegans, the hydrolysis of the nonreducing terminal GlcNAc following the action of GnT I and Golgi α3,6-mannosidase II generates Man 3 GlcNAc 2 which can be core α1-3 fucosylated by FUT-1 (Paschinger et al., 2004 (Paschinger et al., , 2005 . Thus, α1-3 fucosylation of paucimannose glycans by Caenorhabditis FUT-1 does not require the presence of the GnT I-mediated GlcNAc (Paschinger et al., 2004) . Similarly, in Mgat1 1 / Mgat1 1 -null Drosophila mutants, deficient in GnT I activity, trace fucosylation of paucimannose glycans, but not oligomannose glycans, was observed (Sarkar et al., 2006) .
The presence of some α1-6 fucosylated mannose structures (with five or fewer mannose residues) has been attributed to GnT I-dependent fucosylation followed by the action of a β-N-acetylglucosaminidase (and α3,6-mannosidase II for the generation of paucimannose structures) (Zhang et al., 2003) . Similar, fucosylated, paucimannose structures are common in many invertebrates (reviewed in Staudacher et al., 1999) and are also thought to arise from a GnT I-dependent fucosylation followed by the removal of the terminal β1-2-GlcNAc by a membrane-bound β-Nacetylglucosaminidase .
The action of a β-N-acetylglucosaminidase has been proposed to account for the unusual monoantennary braintype glycans that lack β1-2-GlcNAc on the 3-arm (Chen et al., 1998) . Furthermore, β-N-acetylglucosaminidase activity could account for the occurrence of both fucosylated Man 5 GlcNAc 2 and paucimannose glycans in lysosomal glycoproteins such as rat liver alkaline phosphatase (Endo et al., 1996) , porcine cathepsin D (Takahashi et al., 1983) , human β-glucuronidase (Howard et al., 1982) , and bovine α-mannosidase (Faid et al., 2006) . Most of these fucosylated oligomannose structures contained five or fewer mannoses, consistent with fucosylation after GnT I activity. However, core fucosylated Man 6 GlcNAc 2 glycans have been identified in human placental arylsulfatase A indicating the presence of GnT I-independent fucosylation (Hoja-Lukowicz et al., 2000) . Lin and others (1994) previously identified GnT I-independent α1-6 fucosylation in GnT I-deficient (Lec1) Chinese hamster ovary (CHO) cells. The lack of GnT I activity normally stalls the glycan biosynthesis pathway after the glucosidases I and II and the α-mannosidase I activities to leave a Man 5 GlcNAc 2 structure. The discovery of a population of core α1-6 fucosylated Man 5 GlcNAc 2 and Man 4 GlcNAc 2 structures, produced in Lec1 CHO cells, led to the proposal of an alternative activity of the core fucosyltransferase that was independent of β1-2-GlcNAc addition by GnT I. However, earlier studies of the α1,6-fucosyltransferase could not detect this activity in vitro (Wilson et al., 1976; Longmore and Schachter, 1982; Voynow et al., 1991; Shao et al., 1994) . Also, fucosylated oligomannose glycans were not observed in GnT Ideficient Arabidopsis thaliana (von Schaewen et al., 1993; Strasser et al., 2005) . Nonetheless, GnT I-independent fucosylation of oligomannose glycans was demonstrated in a C. elegans triple null mutant lacking any GnT I activity (Zhu et al., 2004) .
In this study, we confirm the presence of core fucosylated Man 5 GlcNAc 2 glycans on a glycoprotein, ligand of inducible co-stimulator (LICOS) (Brodie et al., 2000) , expressed in GnT I-deficient CHO Lec3.2.8.1 cells, and we demonstrate that the abundance of this structure is increased upon expression in the presence of the α-glucosidase inhibitor, Nbutyldeoxynojirimycin (NB-DNJ). Moreover, we report the biosynthesis of a novel core fucosylated monoglucosylated oligomannose glycan, Glc 1 Man 7 GlcNAc 2 Fuc, induced by NB-DNJ treatment. Furthermore, using human embryonic kidney (HEK) 293 cells, we demonstrate the presence of the human GnT I-independent fucosylation pathway by the structural characterization of N-linked glycans from recombinant receptor protein tyrosine phosphatase-μ (RPTPμ) glycoprotein (Ensslen-Craig and Brady-Kalnay, 2004; Aricescu et al., 2006) , expressed in the presence of the inhibitors, swainsonine and kifunensine, and in a HEK 293S cell line devoid of GnT I activity (Reeves et al., 2002) . Domon and Costello (1988) , appeared at the same mass in the spectra of both compounds (m/z = 1012.4, 1072.4, and 869.3, respectively), indicating that the Fuc modification occurs on the terminal GlcNAc at the C6, consistent with a Fucα1-6GlcNAc linkage (Harvey, 2005b) . Further, ions defining the nonreducing moiety of both structures were the same in both spectra ( Figure 2 ) and were identical to those in a reference spectrum of Man 5 GlcNAc 2 .
Results and Discussion

ESI-MS of CHO Lec3.2.8.1-expressed LICOS
Ions defining both the fucosylated and unfucosylated paucimannose glycan, Man 3 GlcNAc 2 , were also identified in the spectra of LICOS (Figure 1 ). These paucimannose structures confirm the presence of a GnT I-independent α-mannosidase activity in CHO Lec3.2.8.1 cells and account for the incomplete digestion by endoglycosidase H (Endo H) of glycoproteins from this expression system (Butters et al., 1999) . To prevent the formation of Endo H-resistant glycans, Butters and others (1999) Interestingly, the relative abundance of the fucosylated Man 5 GlcNAc 2 structure, at ∼38%, is significantly higher than in the spectrum of the LICOS glycans from untreated CHO Lec3.2.8.1 cells.
CID spectra were generated from the parent ions of both the fucosylated and the unfucosylated Glc -18] -ions at an m/z of 647 and 629, respectively, defined the composition of the 6-antennae (Harvey, 2005a) . Other diagnostic ions are indicated in Figure 4 . The identification of the Glc 1 Man 7 GlcNAc 2 Fuc structure demonstrates that the Glcα1-3Manα1-2Manα1-2 saccharides of the 3-antennae do not prevent core fucosylation in CHO cells. Interestingly, there was no evidence of fucosylated Glc 3 Man 7 GlcNAc 2 glycans. Glycosylation sites bearing such triglucosylated structures have not been exposed to calnexin, indicating that core fucosylation may be dependent on the conformation around the glycosylation site. Figure 1 . Ion nomenclature follows the method of Domon and Costello (1988) . This is consistent with a lack of GnT I activity as reported by Reeves and others (2002) and demonstrates that, in contrast to the CHO Lec3.2.8.1 cell line (Figure 1) , there is no GnT I-independent α-mannosidase activity that processes the glycans beyond Man 5 GlcNAc 2 . However, together with the oligomannose series, Man 6-8 GlcNAc 2 , there is an ion at m/z = 1523.5 consistent with the presence of fucosylated Man 5 GlcNAc 2 -2AB ( Figure 5 ). The presence of such fucosylated oligomannose structure, together with the lack of GnT I activity and detectable hybrid-type structures, is indicative of a human GnT I-independent fucosylation pathway analogous to that observed in the CHO expression system.
Swainsonine-treated HEK 293T cells produce fucosylated Man 5 GlcNAc 2 glycans
Man 5 GlcNAc 2 Fuc glycans were also identified following analysis of the N-linked glycans of RPTPμ expressed in HEK 293T cells in the presence of 20 μM of the Golgi α-mannosidase II inhibitor, swainsonine ( Figure 6 ). In contrast to the MALDI-TOF MS analysis of RPTPμ expressed in GnT I-deficient HEK 293S cells (Figure 5 ), the presence of Man 5 GlcNAc 2 Fuc arising from the combined action of GnT I and β-N-acetylglucosaminidase cannot be excluded. Indeed, numerous hybrid-type glycans dominate the spectrum displaying typical GnT I-dependent modifications such as the subsequent addition of galactose, GnT III-mediated bisecting GlcNAc, and core fucosylation. However, analysis of the hybrid-type glycans revealed no evidence of β-N-acetylglucosaminidase activity, such as the identification of bisected oligomannose glycans that could account for GnT I-dependent Man 5 GlcNAc 2 Fuc glycans ( Figure 6 ). Such glycans have been identified in rat brain (Chen et al., 1998) , supporting the ability of β-N-acetylglucosaminidase to remove 2-linked GlcNAc in the presence of bisecting GlcNAc.
Inhibition of a-mannosidase I prevents fucosylation in HEK 293T cells
Further details of the substrate specificity of the fucosyltransferase were revealed by the absence of fucosylated oligomannose glycans on RPTPμ expressed in HEK 293T cells in the presence of 5 μM of the α-mannosidase I inhibitor, kifunensine. MALDI-TOF MS analysis of the N-linked glycans was dominated by the oligomannose glycans Man 7-9 Glc NAc 2 , with a trace of Man 6 GlcNAc 2 (Figure 7 ). Assuming that kifunensine does not inhibit the core fucosyltransferase, the lack of detectable fucosylated derivatives of the Man 7-9 GlcNAc 2 glycans suggests that one or more of the α1-2 mannose residues that extend from the Man 5 GlcNAc 2 core disrupt substrate recognition. Taken together with the NB-DNJ-induced Glc 1 Man 7 GlcNAc 2 structure determined in the CHO Lec3.2.8.1 system, these data suggest that α1-2 mannoses of the 6-antennae prevent GnT I-independent fucosylation.
A model for the core fucosylation pathway
The transfer of β1-2-GlcNAc to the 3-antennae by GnT I is usually regarded as a prerequisite for both core fucosylation and Golgi α-mannosidase II activity and is normally likely to mask the presence of the GnT I-independent fucosylation pathway. The paucity of fucosylated oligomannose glycans in glycoproteins expressed in wild-type mammalian cells can, thus, be attributed to such GnT I-dependent pathways which act to deplete both the predominant substrate (Man 5 GlcNAc 2 ) and the product (Man 5 GlcNAc 2 Fuc) of the GnT I-independent fucosylation pathway (Figure 8 ). In this work, we have exploited cell lines deficient in GnT I to expose the activity of the GnT I-independent fucosylation pathway. Knowledge of such underlying activities within the mammalian glycosylation pathway is important for the precise engineering of glycoproteins and essential when manufacturing therapeutic glycoproteins with controlled glycosylation.
Materials and Methods
Cloning, expression, and purification of LICOS
A cDNA fragment encoding human LICOS extracellular region (residues 1-254) was amplified by polymerase chain reaction (PCR) using prLuc-hLICOS vector as template (from J. James in S.J.D.'s laboratory, University of Oxford) and subcloned into the pEE14 vector of the glutamine synthetase-based gene-expression system (Bebbington and Hentschell, 1987) in frame with a C-terminal LysHis6 tag. The LICOS construct was transfected into CHO Lec3.2.8.1 cells (Stanley, 1981; Chen and Stanley, 2003) using FuGENE 6 transfection reagent (Roche Applied Science, East Sussex, UK). Clones resistant to 15 μM methionine sulfoximine were selected and screened for LICOS expression using dot blot and western blot. One of these clones which expressed LICOS at a level of ∼5 mg/L was selected for large-scale production of protein and was grown in cell factories (Nunc, Roskilde, Denmark) both in the presence and in the absence of 0.25 mM NB-DNJ, as described previously (Butters et al., 1999) . The protein secreted into the tissue culture supernatant was concentrated and buffer exchanged to 20 mM Tris-HCl, 0.5 M NaCl, pH 8.0, by ultrafiltration, and loaded onto a Ni-NTA agarose column, which was then eluted with 300 mM imidazole and subjected to size-exclusion chromatography purification.
Cloning, expression, and purification of RPTPm
A cDNA fragment encoding the human RPTPμ extracellular region (residues 1-742) was amplified by PCR using the phFL vector as template (Gebbink et al., 1993) , a gift from M. Gebbink (University of Utrecht, The Netherlands), and subcloned into the pHL expression vector (Aricescu et al., 2006) in frame with a C-terminal LysHis6 tag.
HEK 293T (ATCC number CRL-1573) and HEK 293S GnT I -/-cells (a gift from H.G. Khorana and P.J. Reeves, Massachusetts Institute of Technology) (Reeves et al., 2002) , 90% confluent, were transiently transfected with polyethyleneimine (Durocher et al., 2002) . The cells were cultured in Dulbecco's modified Eagle's medium (Sigma, Poole, Dorset, UK) supplemented with 10% fetal calf serum (Sigma), L-glutamine, and nonessential amino acids (Invitrogen, Paisley, UK). The serum concentration was lowered to 2% immediately after transfection. Swainsonine and kifunensine (Toronto Research Chemicals, North York, Ontario, Canada) were used at a final concentration of 20 and 5 μM, respectively, and added to the HEK 293T culture medium immediately after transfection. Conditioned media, containing the secreted fusion proteins, were collected 4 days after transfection, centrifuged, sterile filtered, and then diluted with two volumes of phosphatebuffered saline (PBS). The pH was adjusted to 8.0 with 10 mM Tris-HCl. The His-tagged proteins were bound to Ni 2+ -charged chelating Sepharose (Amersham Biosciences, Uppsala, Sweden) in batch mode at 16°C for 4 h, then the beads were packed in BioRad Econo columns, washed with 20 bed volumes of PBS supplemented with 0.1% Tween-20 followed by 20 bed volumes of PBS. Bound proteins were eluted in 100 mM Tris-HCl, pH 8, 500 mM NaCl, 500 mM imidazole, concentrated and subjected to gel filtration using a Superdex 200 HR column (Amersham Biosciences) equilibrated in 100 mM Tris-HCl, pH 8, 500 mM NaCl. Fractions containing the target proteins at >95% purity, as judged by SDS-PAGE, were pooled, quantified, and kept at 4°C.
Enzymatic release of N-linked glycans
Oligosaccharides were released with peptide N-glycosidase F (PNGase F) (Prozyme, San Leandro, CA) from Coomassie blue-stained SDS-PAGE gels containing the target glycoprotein (Küster et al., 1997) . Bands containing ∼10 μg of target glycoprotein were excised from reducing SDS-PAGE gels and washed with 20 mM NaHCO 3 , pH 7.0. The washed gel fragments were dried in a vacuum centrifuge before rehydration with 30 μL of 30 mM NaHCO 3 , pH 7.0, containing 100 U/mL of PNGase F. After incubation for 12 h at 37°C, the enzymatically released N-linked glycans were eluted with water. Salts were removed by a 5-min incubation at room temperature with 200 μL of an acid-activated AG-50W (200-400 mesh) slurry (BioRad, Hercules, CA), which was removed by filtration with a 0.45 μm pore-size filter (Millex-LH, hydrophobic polytetrafluoroethylene). An aliquot of the released glycans was derivatized with 2AB, according to the method described by Bigge and others (1995) .
MALDI-TOF mass spectrometry
Positive-ion MALDI-TOF mass spectra were recorded with a Waters-Micromass TofSpec 2E reflectron-TOF mass spectrometer (Waters-Micromass, Manchester, UK) operated under the following conditions: accelerating voltage, 20 kV; pulse voltage, 3.0 kV; time lag focusing delay, 500 ns (setting 39); and laser-repetition rate, 10 Hz. Aqueous glycan samples (0.5 μL) were mixed on the MALDI target with the matrix (0.5 μL of a saturated solution of 2,5-dihydroxybenzoic acid in acetonitrile), allowed to dry under ambient conditions, and recrystallized from ethanol (0.2 μL).
Negative-ion nano-electrospray mass spectrometry and MS/MS
Negative-ion nano-ESI mass spectra were recorded with a Waters-Micromass Q-Tof Ultima Global mass spectrometer (Waters-Micromass). Samples in methanol : water (1:1, v : v) were infused through Proxeon (Proxeon Biosystems, Odense, Denmark) nanospray capillaries. Operating conditions for the mass spectrometer were: ion source temperature, 120°C; desolvation gas (N 2 ) flow, 50 L/h; infusion capillary voltage, 1.2 kV; RF-1 potential, 180 V; collision gas (argon) pressure, 0.5 bar; collision cell voltage, appropriate to the mass of the glycan (range 60-90 V); mass window for parent ion selection, about 4 Da; scan time, 1 s; and digitization rate, 4 GHz. Spectra were acquired and processed with MassLynx version 4 software (Waters-Micromass).
